Geron Corporation to Present at Needham & Company Biotechnology and Medical Technology Conference
Tuesday June 13, 7:30 am ET
MENLO PARK, Calif.--(BUSINESS WIRE)--June 13, 2006--Geron Corporation (Nasdaq:GERN - News) today announced that Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer, will present an update of the company's product development programs at 1 p.m. EDT on June 14, 2006, at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference.
The update will cover Geron's portfolio of telomerase-based anti-cancer therapies, including GRN163L and GRNVAC1, as well as the company's human embryonic stem cell research in spinal cord injury (GRNOPC1), diabetes (GRNIPC1) and heart disease (GRNCM1).
The audio and slide presentation will be available at the following Web address: wsw.com. A replay will be available for 30 days.
Geron is a Menlo Park, Calif.-based biopharmaceutical company developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases. For more information, visit www.geron.com. |
